The findings yield novel insights into the molecular Tsc1+/− mouse pathology as well as the molecular effects of rapamycin treatment, which is an effective treatment for several clinical symptoms of the tuberous sclerosis complex. The gene discussed is TSC1; the disease is tuberous sclerosis.